Absci Corporation Pricing Public Offering
Absci Corporation (Nasdaq: ABSI), a pioneering clinical-stage biopharmaceutical company focused on using generative AI for drug development, recently announced a significant public offering of its common stock. The offering is set at a public price of $3.00 per share for 16,670,000 shares, potentially yielding gross proceeds of around $50 million, adjusted for any associated discounts or commissions.
Details of the Offering
The public offering also includes a 30-day option for underwriters to acquire an additional 2,500,500 shares under the same terms. All shares offered will be sold directly by Absci, allowing the organization to bolster its capital for ongoing projects.
Utilization of Proceeds
Absci plans to utilize the net proceeds from this offering to advance its innovative research projects, further invest in its Integrated Drug Creation™ platform, and for various operational costs. This strategy highlights Absci's commitment to enhancing drug development through advanced technology.
Underwriters for the Offering
The joint book-running managers leading this public offering include reputable firms such as Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen. The anticipated closing date for this offering, subject to customary conditions, is approximately July 25, 2025.
Regulatory Compliance and Offering Terms
The shares are being issued in accordance with a previously effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Though a preliminary prospectus and accompanying details regarding this offering were submitted, the final version will be available once filed with the SEC. This will ensure compliance with regulatory requirements and protect investor interests.
Absci’s Corporate Vision
Absci is dedicated to revolutionizing drug creation by leveraging its advanced AI capabilities combined with scalable lab technologies. With headquarters located in Vancouver, WA, and an AI Research Lab in New York City, Absci aims to expedite the development of improved biologic therapies for patients globally.
Corporate Communications
For any inquiries regarding the offering, investors and media representatives can reach out to Absci’s investor relations or media departments directly. Alex Khan, the VP of Finance and Investor Relations, is available for investment queries, while press-related communications can be directed to the designated media contact.
Frequently Asked Questions
What is the purpose of Absci's public offering?
The proceeds from the offering will fund Absci's research initiatives and operational costs related to their drug development platform.
Who are the underwriters for the offering?
Major financial institutions including Morgan Stanley, J.P. Morgan, Jefferies, and TD Cowen are acting as the underwriters.
When is the anticipated closing date for the offering?
The offering is expected to close on or around July 25, 2025, pending customary conditions.
How many shares are being offered?
Absci is offering 16,670,000 shares of common stock, with an additional option for underwriters to purchase up to 2,500,500 shares.
What is Absci’s primary focus?
Absci focuses on creating breakthrough therapeutics using generative AI combined with traditional laboratory methods, aimed at developing better biologics.
